These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35224630)

  • 1. Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.
    Kim YK; Kim HS; Park S; Kim HI; Lee SH; Lee DH
    J Antimicrob Chemother; 2022 Apr; 77(5):1353-1364. PubMed ID: 35224630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis.
    Kanji S; Roberts JA; Xie J; Alobaid A; Zelenitsky S; Hiremath S; Zhang G; Watpool I; Porteous R; Patel R
    Ann Pharmacother; 2018 Oct; 52(10):965-973. PubMed ID: 29730948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients.
    Wallenburg E; Ter Heine R; Schouten JA; Raaijmakers J; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Frenzel T; Brüggemann RJM
    Clin Pharmacokinet; 2022 Jun; 61(6):907-918. PubMed ID: 35377133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
    Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
    Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
    Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
    J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study.
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Cho YJ; Corley A; Diehl A; Gilder E; Jakob SM; Kim HS; Levkovich BJ; Lim SY; McGuinness S; Parke R; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Fraser JF; Shekar K; Roberts JA;
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0143821. PubMed ID: 34460303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Population Pharmacokinetics and Pharmacodynamic Approach To Optimize Tazobactam Activity in Critically Ill Patients.
    Kalaria SN; Gopalakrishnan M; Heil EL
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
    Cojutti PG; Morandin E; Baraldo M; Pea F
    Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children with Normal and Augmented Renal Clearance.
    Béranger A; Benaboud S; Urien S; Moulin F; Bille E; Lesage F; Zheng Y; Genuini M; Gana I; Renolleau S; Hirt D; Tréluyer JM; Oualha M
    Clin Pharmacokinet; 2019 Feb; 58(2):223-233. PubMed ID: 29862466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.
    Sukarnjanaset W; Jaruratanasirikul S; Wattanavijitkul T
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):251-261. PubMed ID: 30963365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
    Thorsted A; Kristoffersson AN; Maarbjerg SF; Schrøder H; Wang M; Brock B; Nielsen EI; Friberg LE
    J Antimicrob Chemother; 2019 Oct; 74(10):2984-2993. PubMed ID: 31273375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation.
    Lee DH; Kim HS; Park S; Kim HI; Lee SH; Kim YK
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.